Poor Prognoses of Young Hepatocellular Carcinoma Patients with Microvascular Invasion: A Propensity Score Matching Cohort Study

Table 2

Baseline characteristics of the study participants after PSM.

Variable	Young group	Old group	value
	Gender (male)	71 (84.5%)		70 (83.3%)	0.834
Adjuvant TACE	37 (44.0%)	29 (34.5%)	0.206
Reoperation	10 (11.9%)	5 (6.0%)	0.176
Tumor diameter (cm)			0.583
Tumor number (single)	65 (77.4%)	61 (72.6%)	0.476
GVI	24 (28.6%)	25 (29.8%)	0. 865
Transfusion	8 (9.5%)	10 (11.9%)	0.618
Diabetes	8 (9.5%)	5 (6.0%)	0.386
HBsAg positivity	73 (86.9%)	68 (81.0%)	0.294
AFP (ng/mL) (IQR)	1210.0 (65.4-1210.0)	324.1 (17.2-1210.0)	0.134
Invading adjacent organs	10 (11.9%)	9 (10.7%)	0.808
Anatomic resection	48 (57.1%)	50 (59.5%)	0.754
Well differentiation	33 (39.3%)	42 (50.0%)	0.162
Invasion of liver capsule	22 (26.2%)	25 (29.8%)	0.606
Satellite nodules	11 (13.1%)	9 (10.7%)	0.634
Lymphatic metastasis	4 (4.8%)	3 (3.6%)	0.699
Cirrhosis	40 (47.6%)	37 (44.0%)	0.642
GGT level (U/L) (IQR)	75.5 (43.5-129.5)	67.0 (42.3-119.8)	0.526
ALT level (U/L) (IQR)	43.0 (28.5-66.8)	37.5 (25.0-60.8)	0.124
AST level (U/L) (IQR)	45.5 (33.0-69.5)	47.0 (32.3-71.0)	0.858
TBIL level (mmol/L)			0.852
LYM count (10^9/L)			0.876
WBC count (10^9/L) (IQR)	5.4 (4.4-6.9)	5.4 (4.3-6.7)	0.878
BCLC stage			0.592
A	18 (21.4%)	13 (15.5%)
B-C	64 (78.6%)	71 (84.6%)
Child-Pugh			0.592
A	79 (94.0%)	81 (96.4%)
B	2 (2.4%)	3 (3.6%)
C	3 (3.6%)	0 (0.0%)

Abbreviations: TACE: transcatheter arterial chemoembolization; GVI: giant vascular invasion; AFP: alpha fetoprotein; IQR: interquartile range; GGT: gamma-glutamyl transpeptidase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; LYM: lymphocyte; WBC: white blood cell; BCLC: Barcelona Clinic Liver Cancer.